In this study, we aimed to evaluate the potential association between findings in WM tracts and the CSF level of GAP-43 in patients with AD spectrum to observe the efficacy of GAP-43 as a reliable biomarker in the early detection of patients with cognitive impairment. The gene discussed is GAP43; the disease is Alzheimer disease.